Continuation Protocol for Obstructive Sleep Apnea (OSA)
Launched by APNIMED · Aug 20, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Completion of APC-APN-304 without permanent discontinuation of IMP.
- • Completion of APC-APN-305 without permanent discontinuation of IMP.
- Exclusion Criteria:
- • Participants are excluded from the study if participation would be considered unsafe by the investigator based on the individual's current status.
- • Participants are excluded from the study if participation would be considered unsafe by the investigator based on concomitant therapies.
About Apnimed
Apnimed is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of sleep disorders, particularly obstructive sleep apnea (OSA). With a focus on advancing its proprietary drug candidates, Apnimed aims to address unmet medical needs in the sleep medicine landscape by leveraging cutting-edge research and clinical expertise. The company is committed to improving patient outcomes through scientifically validated approaches and is actively engaged in clinical trials to demonstrate the efficacy and safety of its therapeutic solutions. Apnimed's mission is to transform the management of sleep disorders, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Kansas, United States
San Diego, California, United States
West Palm Beach, Florida, United States
Memphis, Tennessee, United States
Chicago, Illinois, United States
Newton, Massachusetts, United States
Abington, Pennsylvania, United States
Denver, Colorado, United States
Austin, Texas, United States
Dallas, Texas, United States
Wyomissing, Pennsylvania, United States
Suwanee, Georgia, United States
Kansas City, Kansas, United States
Montreal, Quebec, Canada
Little Rock, Arkansas, United States
Anaheim, California, United States
San Antonio, Texas, United States
Riverside, California, United States
North Dartmouth, Massachusetts, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Hazelwood, Missouri, United States
Novi, Michigan, United States
Clearwater, Florida, United States
Glen Burnie, Maryland, United States
Gastonia, North Carolina, United States
Charleston, South Carolina, United States
New Hyde Park, New York, United States
Cincinnati, Ohio, United States
Ocala, Florida, United States
Cerritos, California, United States
Tucson, Arizona, United States
San Antonio, Texas, United States
Toronto, Ontario, Canada
Miami, Florida, United States
Brandon, Florida, United States
Lehigh Acres, Florida, United States
South Ogden, Utah, United States
Pomona, California, United States
Cincinnati, Ohio, United States
Canton, Ohio, United States
Santa Ana, California, United States
Fargo, North Dakota, United States
Miami, Florida, United States
Eatontown, New Jersey, United States
Tampa, Florida, United States
Brandon, Florida, United States
Lake Worth, Florida, United States
Atlanta, Georgia, United States
Los Angeles, California, United States
Saint Louis, Missouri, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Tempe, Arizona, United States
Huntersville, North Carolina, United States
Louisville, Kentucky, United States
Greenville, South Carolina, United States
Denver, North Carolina, United States
North Las Vegas, Nevada, United States
Houston, Texas, United States
Cutler Bay, Florida, United States
Decatur, Georgia, United States
Los Alamitos, California, United States
Rock Hill, South Carolina, United States
Houston, Texas, United States
Daytona Beach, Florida, United States
Chandler, Arizona, United States
Rockville, Maryland, United States
Winter Park, Florida, United States
Henderson, Nevada, United States
Miami, Florida, United States
San Ramon, California, United States
Valdosta, Georgia, United States
Chattanooga, Tennessee, United States
Ottawa, Ontario, Canada
Markham, Ontario, Canada
Sterling Heights, Michigan, United States
Chula Vista, California, United States
Columbia, Maryland, United States
Huntsville, Texas, United States
New Bern, North Carolina, United States
Miami, Florida, United States
Lathrup Village, Michigan, United States
Neptune, New Jersey, United States
Toronto, Ontario, Canada
West Covina, California, United States
Mesa, Arizona, United States
Winter Park, Florida, United States
Phoenix, Arizona, United States
Albuquerque, New Mexico, United States
Tuscaloosa, Alabama, United States
St. Louis, Missouri, United States
Wilmington, North Carolina, United States
Birmingham, Alabama, United States
Kelowna, British Columbia, Canada
Chesterfield, Missouri, United States
Meridian, Idaho, United States
Vienna, Virginia, United States
High Point, North Carolina, United States
Springfield, Massachusetts, United States
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Ron Farkas, MD
Study Director
Apnimed
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported